Patankar SA, Pawar SR, Sharma R, Patankar AP
:max_bytes(150000):strip_icc()/VWH-GettyImages-2158519129-372ed708fbbb4c6e9f472a8218cd52ee.jpg)
CrossRef ADAM15 promotes the progression and metastasis of hepatocellular carcinoma by activating the JNK/p38 pathway Xu Junhui, Su Mengyun Scientific Reports .2026;[Epub] CrossRef Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies Zhenxao Wang, Jun Wu, Qiao Li, Xin Wen Frontiers in Immunology .2026;[Epub] CrossRef Characterization and regulatory mechanism evaluation of C8orf33 in hepatocellular carcinoma through multiomics profiling Wei Gao, Siyi Xing, Mingjiang Liu, Xing Xie, Mei Feng, Zhipeng Quan, Housheng Wang, Zhilong He, Qianxin Hu, Huizhao Su, Shuiping Yu, Zeyuan Li Discover Oncology .2026;[Epub] CrossRef Efficacy and safety of transarterial chemoembolization plus donafenib with or without camrelizumab for unresectable hepatocellular carcinoma: a propensity score matching analysis Qi Zhang, Zhenwu Lei, Hezi Qing, Xingwu Xie Frontiers in Immunology .2026;[Epub] CrossRef Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes Qin Lou, Jiarong Cai, Jianhua Yin Microorganisms .2026

Although uncomfortable and certainly frustrating, constipation that occurs occasionally is not a medical concern
Furthermore, over a third of participants receiving the highest Tirzepatide dose at 15 mg per week, lost at least 25% of their initial body weight, which is over 58 lbs
In June 2025, WeightWatchers shared data from 200 individuals who discontinued GLP-1 medications while following structured lifestyle plans